Conference Call and Webcast Scheduled for Tomorrow, May 18 at 7:00 a.m. (PDT) / 10:00 a.m. (EDT)
EMERYVILLE, Calif., May 17, 2011 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE Amex:NBY) will issue a press release on Wednesday, May 18 announcing the results of its proof-of-concept Phase 2 clinical trial of Aganocide® compound NVC-422 for Adenoviral Conjunctivitis.
The release will be followed the same day by a webcast and conference call during which NovaBay management will discuss the trial results. The webcast and conference call will begin at 7:00 a.m. (PDT) / 10:00 a.m. (EDT) and will be followed by a Q&A session.
Participants calling in for the conference will dial 866-240-5139 (toll free) or 713-481-0091 (toll). A live audio of the conference call will be webcast simultaneously over the internet. Please click on the following link or paste it into your browser:
This event is optimized for MS Windows Media Player version 9. To download go to:
A replay of the webcast will be available shortly after the call and may be accessed at
About NovaBay Pharmaceuticals, Inc.
NovaBay Pharmaceuticals is a clinical-stage biotechnology company focused on developing its proprietary and patented Aganocide® compounds. These are novel, synthetic anti-infectives with activity against bacteria, fungi and viruses, and are being developed to treat and prevent a wide range of local, non-systemic infections with a low likelihood of developing bacterial resistance. NovaBay is focusing its technology on four distinct therapeutic areas: dermatology, ophthalmology, urology and hospital infections. In dermatology, the focus is on developing NVC-422 gel for impetigo and acne. NovaBay has the advantage of being partnered with Galderma, the leading dermatology company in the world. In ophthalmology, the goal is to develop an eye drop for conjunctivitis with Alcon, the world's foremost ophthalmology company. In urology, NovaBay aims to reduce the incidence of urinary catheter blockage and encrustation (UCBE) and the potential for urinary tract infections with an irrigation solution containing NVC-422. In hospital infection, NovaBay is targeting the six-million-patient market of chronic non-healing wounds, such as pressure, venous stasis and diabetic ulcers with its proprietary anti-infective solution, NeutroPhase, which has received two 510(k) clearances from the Food and Drug Administration. For additional information, visit www.novabaypharma.com.
CONTACT: Investors: NovaBay Pharmaceuticals, Inc. Thomas J. Paulson, Chief Financial Officer 510-899-8809 tjpaulson@NovaBaypharma.com Investors and Media: The Investor Relations Group Investor Relations: Adam Holdsworth 212-825-3210 email@example.com Public Relations: Laura Colontrelle 212-825-3210 firstname.lastname@example.org